Catalog No.
Product Name
Application
Product Information
Citations
-
BTK inhibitor
Cinsebrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK), demonstrating significant activity in disrupting BTK-mediated signaling pathways. This compound exhibits potential in cancer research, particularly in hematological malignancies, by inhibiting cell proliferation and survival. Researchers can utilize Cinsebrutinib to investigate the role of BTK in tumor biology and to explore therapeutic strategies targeting BTK in oncology. -
BTK Inhibitor
BTK-IN-14 is a potent Bruton tyrosine kinase (BTK) inhibitor, targeting the BTK signaling pathway involved in B cell antigen receptor (BCR) and Fcγ receptor (FcγR) signaling in B and myeloid cells. This compound is instrumental for the investigation of BTK's role in various pathological conditions, including autoimmune diseases, inflammatory disorders, and certain cancers. Its efficacy makes it a valuable tool for researchers exploring BTK-related therapeutic strategies. -
BTK Inhibitor
BTK-IN-20 is a selective Bruton's tyrosine kinase (BTK) inhibitor and a 1H-pyrazolo[3,4-d]pyrimidine derivative. This compound demonstrates significant anti-inflammatory and anticancer properties, making it a valuable tool for investigating BTK's role in B-cell signaling and associated malignancies. BTK-IN-20 is suitable for research applications focusing on cancer biology and inflammation pathways. -
BTK Inhibitor
BTK-IN-27 is a potent Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 0.2 nM. It exhibits significant anti-proliferative activity in TMD8 cells, with an IC50 of less than 5 nM. This compound is suitable for research applications in cancer, lymphoma, leukemia, and immunological diseases. -
BTK Inhibitor
Midobrutinib is a potent Bruton's tyrosine kinase (BTK) inhibitor, demonstrating an IC50 of 0.813 nM. This compound is valuable for examining the role of BTK in various diseases, particularly in cancer research. By inhibiting BTK, Midobrutinib aids in the investigation of cellular signaling pathways involved in malignancies and potential therapeutic interventions. -
BTK Inhibitor
BTK-IN-11 is a selective inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in the signaling pathways of B cell antigen receptors (BCR) and Fcγ receptors (FcγR) in B cells and myeloid cells. Its potent inhibition of BTK makes it a valuable tool for investigating the role of BTK in various disease contexts, particularly autoimmune diseases, inflammatory disorders, and certain cancers. This compound supports research aimed at understanding BTK-mediated signaling and its implications in disease pathogenesis. -
GSTO1/BTK Inhibitor
GSTO1-IN-2 is a dual covalent inhibitor targeting GSTO1 and Bruton's tyrosine kinase (BTK), demonstrating IC50 values of 441 nM and 6.2 nM, respectively. This compound exhibits potent inhibitory activity, making it a valuable tool for research in oncology and autoimmunity. Its ability to effectively modulate key pathways involved in these biological processes supports investigations into therapeutic applications. -
BTK Inhibitor
BTK-IN-22 is a highly selective Bruton's tyrosine kinase (BTK) inhibitor, demonstrating an IC50 value of 0.9 nM. It also effectively inhibits BLK and BMX kinases with IC50 values of 1.4 nM and 1.2 nM, respectively. This compound is valuable for research focused on B-cell malignancies and related signaling pathways, providing a useful tool for exploring the therapeutic potential of BTK inhibition. Its improved kinase selectivity compared to existing inhibitors enhances its utility in biological studies. -
BTK Inhibitor
BTK-IN-18 is a potent, reversible Bruton’s Tyrosine Kinase (BTK) inhibitor with an IC50 of 0.002 µM. This compound effectively inhibits the expression of CD69 and CD86 in vivo, demonstrating its potential in modulating B-cell receptor signaling pathways. BTK-IN-18 is suitable for research applications in hematological malignancies and autoimmune diseases, facilitating studies on B cell function and therapy development. -
BTK Inhibitor
BTK-IN-41 is a selective Bruton’s tyrosine kinase (BTK) inhibitor with an IC50 value of 5.4 nM. This compound effectively inhibits diffuse large B cell lymphoma cell line TDM-8 with an IC50 of 13.8 nM. BTK-IN-41 is valuable for investigating the role of BTK in B cell malignancies and for evaluating potential therapeutic strategies in hematological cancers. -
Btk Inhibitor
BTK-IN-33 is a Bruton’s tyrosine kinase (Btk) inhibitor that demonstrates significant anticancer activity. This compound selectively targets the Btk pathway, which is crucial for B-cell receptor signaling and survival. BTK-IN-33 is primarily utilized in research investigating B-cell malignancies and provides potential therapeutic insights into related cancers. -
BTK Inhibitor
PF-303 is a highly selective, oral inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 of 0.64 nM. This compound forms a reversible covalent bond with the Cys481 residue of BTK, allowing for targeted modulation of BTK activity without the concerns associated with irreversible inhibitors. PF-303 is valuable for investigating the role of BTK in immune system functioning, particularly in analyzing B-cell subsets, antibody production, and T-cell activation dynamics. -
BTK Inhibitor
BTK-IN-40 is a potent Bruton’s tyrosine kinase (BTK) inhibitor, designed to selectively inhibit BTK activity. This compound exhibits significant anti-inflammatory and anti-proliferative effects, making it a valuable tool for research in autoimmune diseases and hematological malignancies. BTK-IN-40’s targeted action facilitates the exploration of BTK's role in various signaling pathways and its therapeutic potential in related conditions. -
BTK Inhibitor
WS-11 is a non-covalent reversible inhibitor of Bruton's tyrosine kinase (BTK), exhibiting IC50 values of 3.9 nM and 2.2 nM for wild-type and C481S mutant BTK, respectively. Its potent activity arises from the formation of strong π-π interactions with phenylalanine 540 and p-π interactions with lysine 430 within the active site, complemented by robust hydrogen bonding. WS-11 serves as a valuable tool for studying BTK-related signaling pathways and evaluating therapeutic strategies in disorders such as lymphoma and autoimmune diseases. -
BTK PROTAC Degrader
DDa-1 is a potent BTK PROTAC degrader with a DC50 of 90 nM, designed to facilitate the targeted degradation of Bruton's Tyrosine Kinase (BTK) in cellular systems. This compound effectively utilizes a novel mechanism involving DCAF1 binding, a distinct linker, and a specific BTK ligand to enhance selectivity and efficacy. DDa-1 is primarily utilized in research applications focusing on BTK-related signaling pathways and therapeutic strategies against B-cell malignancies. -
BTK Inhibitor
BTK-IN-26 is a highly potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting IC50 values of 0.7 nM for wild-type BTK and 0.8 nM for the C481S mutant. This compound is suitable for research in cancer and autoimmune diseases, facilitating studies on BTK's role in these conditions. Its selective inhibition allows for effective elucidation of BTK-dependent signaling pathways and therapeutic intervention. -
BTK Inhibitor
BTK-IN-34 is a selective Bruton’s Tyrosine Kinase (BTK) inhibitor. It demonstrates significant antiproliferative activity in RAMOS cells by specifically inhibiting phosphorylated BTK (Tyr223), while leaving upstream kinases Lyn and Syk unaffected. This compound is valuable for research into B cell receptor signaling and the development of therapies targeting B cell malignancies. -
BTK Inhibitor
Birelentinib is a potent, selective, non-covalent inhibitor of BTK and LYN tyrosine kinases, effective in penetrating the blood-brain barrier. It demonstrates concentration-dependent antiproliferative activity in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) lines with BTK resistance mutations, such as C481X and V416L. By disrupting both BTK-dependent and independent signaling pathways of the B-cell receptor (BCR), Birelentinib impedes tumor cell proliferation and promotes apoptosis. This compound is valuable in research aimed at overcoming resistance to existing BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL). -
BLK/BTK Inhibitor
BLK-IN-1 is a selective covalent inhibitor targeting B-Lymphoid Tyrosine Kinase (BLK) and Bruton Tyrosine Kinase (BTK), with IC50 values of 18.8 nM and 20.5 nM, respectively. This compound is valuable for investigating the role of these kinases in cancer biology and exploring potential therapeutic applications. Its specificity makes it suitable for studying the molecular mechanisms underlying malignancies associated with BLK and BTK activity. -
PROTAC BTK Degrader
BCPyr is a PROTAC-class degrader specifically targeting Bruton’s Tyrosine Kinase (BTK), exhibiting a DC50 of 800 nM. This compound integrates a BTK ligand (ligand 11) and an E3 ubiquitin ligase ligand (ligand 20) through a pyrazinyl methanol linker. BCPyr facilitates the targeted degradation of BTK, making it a valuable tool for studying diseases where BTK is implicated, such as certain hematological malignancies. -
BTK Inhibitor
HBC-12551 is a potent orally active Bruton’s tyrosine kinase (BTK) inhibitor, demonstrating an IC50 of 1.31 nM in HEK293 cells for BTK and 2.18 nM for the BTKC481S mutant. This compound exhibits significant antitumor activity, particularly in the context of diffuse large B-cell lymphoma. HBC-12551 serves as a valuable tool for research into targeted therapies for B-cell malignancies. -
BTK Inhibitor
BTK-IN-10 is a highly potent Bruton’s Tyrosine Kinase (BTK) inhibitor, exhibiting IC50 values of less than 5 nM against both wild-type BTK and the C481S mutant variant. This compound is ideal for studying BTK signaling pathways and evaluating therapeutic strategies in hematological malignancies. Its efficacy in inhibiting BTK makes it a valuable tool for researchers investigating the role of BTK in immune regulation and cancer biology. -
Pan-BTK Inhibitor
GNE-431 is a potent, selective, noncovalent pan-BTK inhibitor that targets various BTK mutants, including C481R, T474I, and T474Ms. It demonstrates significant biological activity with an IC50 of 3.2 nM against wild-type BTK and 2.5 nM against the C481S mutant. GNE-431 is a valuable tool for research into hematological disorders and autoimmune diseases, providing insights into the modulation of B-cell signaling pathways. -
BTK Inhibitor
BTK-IN-21 is a potent Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 33 nM. It exhibits significant inhibitory effects on BTK activity, making it a valuable tool for research applications related to cancer and autoimmune diseases. This compound enables the exploration of BTK signaling pathways and supports the development of targeted therapies in these areas. -
Btk Inhibitor
BTK Inhibitor 19 is a highly selective covalent inhibitor of Bruton’s tyrosine kinase (BTK), with an IC50 value of 2.7 nM. This compound effectively modulates BTK activity, playing a crucial role in pathways associated with B cell receptor signaling. It is particularly valuable in research applications focused on B cell malignancies and autoimmune diseases, facilitating the exploration of therapeutic strategies targeting BTK. -
Btk Inhibitor
Civorebrutinib is a selective inhibitor of Bruton's tyrosine kinase (Btk), which plays a critical role in B cell receptor signaling. This compound exhibits significant antineoplastic activity, making it a valuable tool for research into B cell malignancies and related disorders. Its ability to modulate B cell function positions Civorebrutinib as a candidate for studies examining targeted therapies in hematological cancers. -
BTK Inhibitor
RN941 is a potent Bruton's tyrosine kinase (BTK) inhibitor, targeting the BTK signaling pathway. It exhibits significant biological activity in modulating B-cell signaling, making it a valuable tool in the study of rheumatoid arthritis and B-cell malignancies. RN941 is suitable for research applications involving disease mechanisms and therapeutic strategies in these conditions. -
BTK Mutant Inhibitor
AMX5160 is an orally active Bruton's tyrosine kinase (BTK) inhibitor, specifically targeting the mutant BTKC481S with an IC50 of 0.98 nM. This reagent is useful for investigating the role of BTK in various malignancies, including leukemia and lymphoma, as well as in research related to multiple sclerosis and other autoimmune disorders. -
Topoisomerase I Inhibitor
Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I, a key enzyme involved in DNA replication and repair. This compound disrupts the enzyme's catalytic activity, leading to the accumulation of DNA damage and ultimately inducing apoptosis in cancer cells. Topoisomerase I inhibitor 11 is primarily utilized in cancer research, particularly for studying mechanisms of drug resistance and the therapeutic potential of targeting Topoisomerase I in various malignancies. -
BTK/IKZF1/3 PROTAC Ligand
BTK/IKZF1/3 ligand 1 is a PROTAC ligand targeting Bruton's tyrosine kinase (BTK) and the Ikaros family zinc finger proteins (IKZF1/3). This compound can be conjugated with E3 ligase ligands and linkers to produce PROTAC BTK/IKZF1/3 Degrader-1, facilitating targeted protein degradation. It is valuable for cancer research, supporting investigations into therapeutic strategies aimed at modulating BTK and IKZF1/3 activity in malignant cells. -
PF-06250112 Racemate
(Rac)-PF-06250112 is a racemic mixture of PF-06250112, a highly selective and orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK). This compound demonstrates potent inhibitory activity against BTK as well as BMX nonreceptor tyrosine kinase and TEC. Its selectivity and efficacy make it a valuable tool for research applications focused on B cell malignancies and other diseases associated with aberrant BTK signaling. -
BTK Inhibitor
BTK-IN-8 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), exhibiting a binding affinity with an IC50 of 0.22 nM and a Kd of 0.91 nM. This compound demonstrates significant cellular activity against whole blood CD69, with an IC50 of 0.029 µM. BTK-IN-8 is primarily used in research focused on hematological malignancies and autoimmune disorders, providing insights into BTK-mediated signaling pathways. -
BTK PROTAC Degrader
PROTAC BTK Degrader-12 is a PROTAC (Proteolysis Targeting Chimera) designed to selectively degrade Bruton's tyrosine kinase (BTK). It facilitates the targeted ubiquitination and subsequent proteasomal degradation of BTK, resulting in diminished signaling pathways associated with B-cell malignancies and autoimmune disorders. This compound serves as a valuable tool in research investigating BTK's role in disease mechanisms and therapeutic interventions. -
Btk Inhibitor
RN983 is a highly selective inhibitor of Bruton's tyrosine kinase (Btk), demonstrating potent inhibition of immunoglobulin G (IgG) production in B-cells with an IC50 of 2.5 nM, and prostaglandin D2 (PGD2) production in mast cells with an IC50 of 8.3 nM. This compound serves as a valuable tool for investigating the roles of Btk in B-cell signaling and mast cell activation, making it relevant in the study of asthma and other allergic diseases. -
BTK Inhibitor
BTK-IN-36 is a potent Bruton’s Tyrosine Kinase (BTK) inhibitor, exhibiting an IC50 of 0.5 nM. This compound effectively inhibits BTK signaling pathways, which are crucial for B-cell receptor signaling and have implications in various cancers. BTK-IN-36 is applicable in cancer research, particularly in studies exploring targeted therapies for B-cell malignancies. -
RET Inhibitor
RET-IN-14 is a highly selective RET inhibitor that demonstrates potent inhibition with IC50 values of less than 0.51 nM for wild-type RET and varying nanomolar activity against RET mutations (G810R and V804M) as well as BTK and its C481S mutant. Its exceptional efficacy positions RET-IN-14 as a valuable tool for investigating RET-driven tumors and exploring therapeutic strategies in cancer research. -
BTK Inhibitor
BTK-IN-15 is a highly potent inhibitor of Bruton's tyrosine kinase (BTK), exhibiting an IC50 value of 0.7 nM. This compound demonstrates exceptional selectivity for BTK and displays significant antitumor activity. Additionally, BTK-IN-15 is known to induce apoptosis, making it a valuable tool for research in cancer biology and the development of targeted therapies. -
BTK Inhibitor
VA5 is a potent Bruton’s tyrosine kinase (BTK) inhibitor, designed to selectively inhibit BTK activity. This compound plays a crucial role in modulating B-cell signaling pathways and has potential applications in studying various diseases associated with dysregulated BTK activity, including certain hematological malignancies and autoimmune disorders. VA5 serves as a valuable tool in preclinical research to further investigate the therapeutic potential of targeting BTK. -
BTK Degrader
PROTAC BTK Degrader-11 is a potent PROTAC designed to selectively degrade Bruton's tyrosine kinase (BTK), exhibiting a DC50 of 1.7 nM. This compound facilitates targeted protein degradation, offering significant potential in cancer research applications by modulating BTK-related pathways. The structure includes a target protein ligand, a linker, and an E3 ligase component, allowing for effective engagement of the ubiquitin-proteasome system. -
BTK Inhibitor
BTK-IN-38 is a potent inhibitor of Bruton's tyrosine kinase (BTK). It effectively inhibits the proliferation of DOHH2 and BT474 cancer cell lines, exhibiting IC50 values of 114 nM and 340 nM, respectively. This compound is of particular interest in research applications targeting B-cell malignancies and related signaling pathways. -
BTK PROTAC Degrader
TQ-3959 is an orally bioavailable BTK PROTAC degrader that demonstrates a DC50 of 14.6 nM. It exhibits potent antiproliferative effects on both wild-type BTK and the C481S mutant BTK cell lines. In vivo, TQ-3959 effectively inhibits tumor growth in female NOD-SCID mice bearing TMD-8 xenografts. This compound is valuable for investigating B-cell malignancies, including lymphoma. -
BTK Inhibitor
BTK-IN-23 is a selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 12.8 nM. This compound also exhibits inhibitory effects on BMX and BLK, with IC50 values of 5.7 nM and 35.6 nM, respectively. BTK-IN-23 demonstrates enhanced kinase selectivity compared to Ibrutinib, making it a valuable tool for research in cancer and autoimmune disease therapies, particularly in studies focusing on B-cell signaling pathways. -
BTK Inhibitor
BTK-IN-43 is a selective inhibitor of Bruton's tyrosine kinase (BTK) with an IC50 value of 21.6 nM. This compound is capable of oral administration and exhibits potent activity against BTK-mediated signaling pathways. It is primarily utilized in research applications focused on hematological malignancies and immune disorders driven by aberrant BTK activity. -
BTK Degrader
BTK Degrader-2 is a potent dual-functional agent designed to degrade Bruton's tyrosine kinase (BTK) via the ubiquitin-proteasome pathway. This compound is valuable for investigating B-cell-related disorders by providing insights into BTK's role in cellular processes and disease mechanisms. Its application in research can enhance the understanding of therapeutic strategies targeting B-cell malignancies and other related diseases. -
BTK Inhibitor
HZ-A-005 is a potent and selective covalent inhibitor of Bruton’s tyrosine kinase (BTK), a critical regulator in B cell receptor signaling. This compound demonstrates significant anti-tumor activity, effectively reducing tumor growth in xenograft mouse models. HZ-A-005 is valuable for research applications focused on B cell malignancies and the study of BTK's role in various signaling pathways. -
Btk Inhibitor
BTK-IN-32 is a selective Bruton’s tyrosine kinase (BTK) inhibitor that effectively modulates BTK activity. It uniquely activates both full-length BTK and smaller multidomain fragments, rather than solely targeting the isolated kinase domain. This compound is useful in research applications focused on B-cell signaling pathways and the development of therapies for related hematological malignancies. -
Btk Degrader
BTK Ligand 1 is a selective ligand for Bruton’s tyrosine kinase (Btk) that facilitates targeted protein degradation via a PROTAC (proteolysis-targeting chimera) approach. By linking with an E3 ligase ligand through a PROTAC linker, this compound enables the targeted degradation of Btk. BTK Ligand 1 is valuable for researching chronic lymphocytic leukemia (CLL) and other B-cell malignancies, providing insights into the therapeutic potential of Btk inhibition in oncology. -
BTK Inhibitor
BTK Inhibitor 20 is a highly selective inhibitor of Bruton’s Tyrosine Kinase (BTK), exhibiting an IC50 value of 8 nM. This compound effectively modulates the BTK signaling pathway, playing a critical role in B-cell receptor signaling and related processes. It is valuable for research focused on B-cell malignancies, autoimmune diseases, and other conditions where BTK activity is implicated. -
BTK Inhibitor
BTK-IN-25 is a highly potent inhibitor of Bruton’s tyrosine kinase (BTK), demonstrating an IC50 of 0.77 nM against the BTK(C481S) mutant and 1 nM in DOHH2 cells. This compound is valuable for exploring BTK-related signaling pathways and potential therapeutic interventions in B-cell malignancies. Its selective inhibition of BTK makes it a useful tool for research applications focused on the modulation of immune responses and the development of targeted cancer therapies. -
BTK Inhibitor
BTK-IN-12 is a potent Bruton’s Tyrosine Kinase (BTK) inhibitor, with IC50 values of 1.2 nM for wild-type BTK and 0.8 nM for the mutated BTK (C481S). This compound selectively targets BTK, a key regulator in B-cell receptor signaling, making it valuable for research in hematological malignancies and autoimmune disorders. BTK-IN-12 can facilitate the study of therapeutic approaches for conditions associated with dysregulated B-cell activity.
